Share this article
Share this article
CHICAGO, Feb. 17, 2021 /PRNewswire/ RLDatix, the leading global provider of intelligent patient safety solutions, announced today that it has signed a Memorandum of Understanding (MOU) with Mitsubishi UFJ Research and Consulting Co., Ltd. (MURC) to collaborate on projects that utilize technology to improve patient and health worker safety in low- and middle- income countries (LMICs). It also establishes an agreement to share information on patient safety related opportunities in the long-term care market in Japan.
According to the World Health Organization, the occurrence of adverse events due to unsafe care is likely one of the 10 leading causes of death and disability in the world. The situation is especially dire in LMICs, with 134 million adverse events resulting in 2.6 million deaths each year. The WHO also states that investments in reducing preventable harm can lead to significant financial savings, highlighting the need for initiativ
Share this article
Share this article
NASHVILLE, Tenn., Feb. 17, 2021 /PRNewswire/ ExEm® Foam Inc announced today that ExEm® Foam ((air polymer-type A) intrauterine foam), the only FDA-approved contrast agent for ultrasound tubal patency testing, is now available at select fertility clinics nationwide. The Foam procedure, a new ultrasound technique of hysterosalpingo foam sonography (HyFoSy), uses ExEm® Foam to assess whether there may be a blockage in the fallopian tubes in women with known or suspected infertility. The innovative imaging technique offers a less complicated and less invasive alternative to laparoscopy and dye, the gold standard for diagnosing tubal patency. The outpatient tubal assessment is also associated with significantly lower pain scores as compared to the standard of care, X-ray hysterosalpingography (HSG), and does not require the use of radiation and iodine.
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases. In cancer, AXL suppresses the body s immune response to tumours and drives cancer treatment failure across many indications. AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single ag
Perceptive Solutions Awarded CIO Review s 20 Most Promising Workflow Solution Providers
The annual award recognizes the top twenty companies that are at the forefront of providing workflow solutions and transforming businesses.
News provided by
Share this article
Share this article
STEVENS POINT, Wis., Feb. 17, 2021 /PRNewswire/ Perceptive Solutions, Inc., maker of WoundZoom Wound Centric EMR and three-dimensional (3D) imaging hardware solutions, today announced being awarded as one of CIO Review s 20 Most Promising Workflow Solution Providers of 2021.
This annual award recognizes the top twenty companies that are at the forefront of providing workflow solutions and transforming businesses. We are thrilled to be recognized as a workflow solution provider in a segment of healthcare, wound care, that has lagged behind in terms of digital transformation, said Mark Lacerte, President of Perceptive Solutions. Our WoundZoom solution helps healthcare providers deliver more effi
/PRNewswire/ ESMO, the leading organisation for medical oncology, launches an important new service for rapidly disseminating research to accelerate the.